Versartis Selects Comprehend Systems - Applied Clinical Trials


See our 2013 Buyers Guide Digital Edition.
Versartis Selects Comprehend Systems

Source: Company News Release

Biopharmaceutical company Versartis, Inc. has selected Comprehend Systems to help facilitate compilation of real-time study information and subject data. The market’s only cloud-based platform with the ability to easily access and analyze data from any clinical IT system, Comprehend Clinical enables all users, including clinical operations and medical affairs, to have immediate access to critical site data for optimal trial management and safety review.

Versartis is developing VRS-317, a novel, long-acting form of recombinant human growth hormone for the treatment of growth hormone deficiency (GHD). VRS-317 is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance and therefore treatment outcomes. The company is currently completing a Phase II clinical trial of VRS-317 in children with GHD.

Versartis selected Comprehend for its ability to provide real-time access to the data in its studies and to simplify what had been a time-consuming process managing multiple data sources. With Comprehend, the company’s clinical operations team has a complete view of every study and access to study information real-time via intuitive dashboards. And once created, those dashboards can be re-used and updated automatically.

“Comprehend connects to all of our clinical trial data, enabling us to view and summarize study progress easily, with little time and effort,” said Eric Humphriss, vice president, clinical operations of Versartis. “Comprehend Clinical was up and running and fully deployed in just three months, which met our already high expectations. The level of expertise across their entire professional services team is excellent.”

“We understand the burdens facing today’s biotech and pharmaceutical companies, and founded Comprehend with companies like Versartis in mind – companies committed to bringing innovative new therapies to market as quickly as possible,” said Rick Morrison, CEO and co-founder of Comprehend. “By removing the inherent barriers that come with multiple data systems and sources, we enable a better and faster clinical research process, and allow Versartis to run the most efficient clinical trials possible, while staying focused on patient care and treatments."


blog comments powered by Disqus



8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
View Results
Untitled Document
Source: Company News Release,
Click here